PODD Insulet Corporation

Q1 2025 10-Q

Filed: May 9, 2025Period ending Mar 31, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Insulet Corporation (PODD) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 9, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• Continued supply chain disruptions impacting production capacity and inventory levels
• Exposure to competitive threats from new insulin delivery technologies

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$569M

Net Income

$35M

Gross Margin

71.9%

Operating Margin

15.6%

Net Margin

6.2%

Source: XBRL data from Insulet Corporation Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Insulet Corporation Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Insulet Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.